公开(公告)号：CA2352552C

公开(公告)日：2008-12-02

申请号：CA2352552

申请日：1991-04-22

Applicant: VIVUS INC

Inventor： BERGGREN RANDALL G ,  GALE ROBERT M ,  PLACE VIRGIL A

IPC: A61K9/02 ,  A61K31/5575 ,  A61F5/41 ,  A61K9/00 ,  A61K31/417 ,  A61K31/517 ,  A61M31/00 ,  A61P15/12

Abstract: Erectile dysfunction, particularly impotence, priapism and Peyronie's disease is treated by the transurethral administration of a therapeutically effective agent. The agents are administered to the urethra by means of a penile insert (1) having a rapidly releasing coating (4) containing the agent on its exterior surface or by means of an inserter (27) carrying an agent containing dose of agent (31) which can be displaced into the urethra.

公开(公告)号：CA2186382C

公开(公告)日：2001-09-11

申请号：CA2186382

申请日：1995-03-20

Applicant: VIVUS INC

Inventor： PLACE VIRGIL A

IPC: A61B5/00 ,  A61B5/055 ,  A61B5/103 ,  A61B5/11 ,  A61B5/20 ,  A61B8/06 ,  A61F5/41 ,  A61K9/00 ,  A61K49/00 ,  A61M31/00 ,  A61B5/02 ,  A61B8/00

Abstract: A method for diagnosing vasculogenic erectile dysfunction, including vasculogenic impotence and Peyronie's syndrome, is provided. The method involves transurethral administration of a vasodilating agent to induce an erection, followed by hemodynamic evaluation using duplex ultrasonography, NMR, angiography, or the like. Kits for conducting the diagnostic method are provided as well, as are methods of treatment based on the diagnostic conclusion. The kits for diagnosing erectile dysfunction comprise a vasodilating agent (4) effective to induce erection of the penis, a drug delivery means (1, 11, or 49) for administering the vasodilating agent transurethrally, a container (15 or 55) for housing the agent and drug delivery means, and written instructions for using the agent and the drug delivery means.

公开(公告)号：CA2305293A1

公开(公告)日：1999-05-06

申请号：CA2305293

申请日：1998-10-28

Applicant: VIVUS INC

Inventor： PLACE VIRGIL A ,  SMITH WILLIAM L ,  DOHERTY PAUL C JR

IPC: A61K45/00 ,  A61F5/41 ,  A61K9/00 ,  A61K31/00 ,  A61K31/135 ,  A61K31/137 ,  A61K31/357 ,  A61K31/4045 ,  A61K31/4178 ,  A61K31/4468 ,  A61K31/517 ,  A61K31/519 ,  A61K31/551 ,  A61K31/5513 ,  A61K45/06 ,  A61P15/00 ,  A61K31/404 ,  A61F2/02 ,  A61K31/40

Abstract: A method is provided for delaying the onset of ejaculation in an individual. The method preferably involves administration of an antidepressant drug, a serotonin agonist or antagonist, an adrenergic agonist or antagonist, an adrenergic neurone blocker, or a derivative analog thereof, within the context of an effective dosing regimen. The preferred mode of administration is transurethal; however, the selected active agent may also be delivered via intracavernosal injection or using alternative routes. Pharmaceutical formulations and kits are provided as well.

公开(公告)号：AU3402497A

公开(公告)日：1998-01-07

申请号：AU3402497

申请日：1997-06-13

Applicant: VIVUS INC

Inventor： PLACE VIRGIL A

IPC: A61F2/00 ,  A61F5/41

Abstract: A venous flow control device is provided for assisting in the maintenance of a penile erection or in preventing urinary incontinence. The device is a tubular structure adapted to be secured in a loop configuration about the penis to provide an adjustable radial constrictive force about the base of the penis. Methods for using the device are also provided.

公开(公告)号：BR9607365A

公开(公告)日：1997-12-30

申请号：BR9607365

申请日：1996-03-07

Applicant: VIVUS INC

Inventor： PLACE VIRGIL A

IPC: A61K38/00 ,  A61F5/41 ,  A61K9/00 ,  A61K31/445 ,  A61K31/48 ,  A61K31/505 ,  A61K31/54 ,  A61K31/557 ,  A61K33/00 ,  A61K45/00 ,  A61P9/00 ,  A61P13/02 ,  A61P15/00 ,  A61M31/00

Abstract: A method is provided for preventing erectile dysfunction, particularly vasculogenic impotence, in a male individual. The method involves periodic administration of a vasoactive agent throughout a 24-hour period. The agent and dosage regimen are selected such that regularly increased blood flow to the penis is achieved, in turn preventing arterial occlusion and vascular deterioration of the muscular fibers of the vessels and collagen fibers of the cavernosal tissue.

公开(公告)号：MX9707038A

公开(公告)日：1997-11-29

申请号：MX9707038

申请日：1996-03-07

Applicant: VIVUS INC

Inventor： PLACE VIRGIL A

IPC: A61K38/00 ,  A61F5/41 ,  A61K9/00 ,  A61K31/445 ,  A61K31/48 ,  A61K31/505 ,  A61K31/54 ,  A61K31/557 ,  A61K33/00 ,  A61K45/00 ,  A61P9/00 ,  A61P13/02 ,  A61P15/00 ,  A61K09/00 ,  A61F05/41 ,  A61M31/00

Abstract: El uso de un agente vasoactivo para preparar composiciones para prevenir la disfuncion eréctil, particularmente la impotencia vasculogénica, en un individuo masculino, mediante la administracion periodica de dicha composicion durante un período de 24 horas; la composicion y el régimen de dosis se selecciona de modo que se logra un flujo de sangre regularmente incrementado hacia el pene, previniendo a su vez la oclusion arterial y el deterioro vascular de las fibras vasculares de los vasos y fibras de colágena del tejido cavernoso.

公开(公告)号：NO300083B1

公开(公告)日：1997-04-07

申请号：NO924032

申请日：1992-10-19

Applicant: VIVUS INC

Inventor： PLACE VIRGIL A ,  GALE ROBERT M ,  BERGGREN RANDALL G

IPC: A61F5/41 ,  A61K9/00 ,  A61K9/02 ,  A61K31/417 ,  A61K31/517 ,  A61K31/5575 ,  A61M31/00 ,  A61P15/12

Abstract: Erectile dysfunction, particularly impotence, priapism and Peyronie's disease is treated by the transurethral administration of a therapeutically effective agent. For impotence, the agents include vasodilators, for priapism, the agents include vasoconstrictors and for Peyronie's disease, the agents include anti-inflammatory agents. The agents are preferably administered to the urethra by means of a penile insert (1) having a rapidly releasing coating (4) of the agent on its exterior surface or by means of an inserter (27) carrying a load of agent (31) which can be displaced into the urethra.

公开(公告)号：NO963916A

公开(公告)日：1996-11-21

申请号：NO963916

申请日：1996-09-19

Applicant: VIVUS INC

Inventor： PLACE VIRGIL A

IPC: A61B5/00 ,  A61B5/055 ,  A61B5/103 ,  A61B5/11 ,  A61B5/20 ,  A61B8/06 ,  A61F5/41 ,  A61K9/00 ,  A61K49/00 ,  A61M31/00 ,  A61B19/00

CPC classification number: A61B5/4393 ,  A61F5/41 ,  A61K9/0034 ,  A61M31/00

公开(公告)号：CA2217863A1

公开(公告)日：1996-10-17

申请号：CA2217863

申请日：1996-04-10

Applicant: VIVUS INC ,  US HEALTH

Inventor： PLACE VIRGIL A ,  HANAMOTO MARK S ,  SAAVEDRA JOSEPH E ,  DOHERTY PAUL C ,  KEEFER LARRY K

IPC: A61M3/00 ,  A61K31/13 ,  A61K31/44 ,  A61K31/655 ,  A61K31/785 ,  A61K47/48 ,  A61P13/02 ,  A61P15/00 ,  A61P15/10 ,  C08F8/30 ,  A61K33/00

Abstract: A method of treatment for impotency is provided. The method involves the administration of nitric oxide by a nitric oxide-releasing agent capable of providing a penile erection-inducing amount of nitric oxide to the corpus cavernosum of the penis of an impotent male animal. Also provided is a nitric oxide delivery means for use in the method.

公开(公告)号：CA2305394C

公开(公告)日：2006-12-12

申请号：CA2305394

申请日：1998-10-28

Applicant: VIVUS INC

Inventor： DOHERTY PAUL C JR ,  PLACE VIRGIL A ,  SMITH WILLIAM L

IPC: A61K9/02 ,  A61K31/485 ,  A61K31/00 ,  A61K31/343 ,  A61K31/381 ,  A61K31/4015 ,  A61K31/4164 ,  A61K31/4166 ,  A61K31/426 ,  A61K31/437 ,  A61K31/4439 ,  A61K31/444 ,  A61K31/47 ,  A61K31/4704 ,  A61K31/4709 ,  A61K31/4745 ,  A61K31/496 ,  A61K31/50 ,  A61K31/501 ,  A61K31/502 ,  A61K31/5025 ,  A61K31/505 ,  A61K31/517 ,  A61K31/519 ,  A61K31/52 ,  A61K31/522 ,  A61K31/5377 ,  A61K31/538 ,  A61K31/549 ,  A61K31/5513 ,  A61K45/00 ,  A61K45/06 ,  A61P15/10

Abstract: A method is provided for treating erectile dysfunction in a mammalian male individual. The method involves the local administration of a phosphodiesterase inhibitor or a pharmaceutically acceptable salt, este r, amide or derivative thereof, within the context of an effective dosing regimen. A preferred mode of administration is transurethral. Pharmaceutical formulations and kits are provided as well.